1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Market Overview
3.1. Introduction

4. Competitive Landscape
4.1. FPNV Positioning Matrix
4.1.1. Quadrants
4.1.2. Business Strategy
4.1.3. Product Satisfaction
4.2. Market Ranking Analysis
4.3. Market Share Analysis, By Key Player
4.4. Competitive Scenario
4.4.1. Merger & Acquisition
4.4.2. Agreement, Collaboration, & Partnership
4.4.3. New Product Launch & Enhancement
4.4.4. Investment & Funding
4.4.5. Award, Recognition, & Expansion

5. Company Usability Profiles
5.1. Astellas Pharma Inc
5.2. AstraZeneca PLC
5.3. Bristol Myers Squibb
5.4. C.H. Boehringer Sohn AG & Ko. KG
5.5. Celgene Corporation
5.6. Eisai Co., Ltd
5.7. Eli Lilly and Company
5.8. F. Hoffmann-La Roche Ltd
5.9. GlaxoSmithKline PLC
5.10. Merck KGaA
5.11. Novartis International AG
5.12. Orion Corporation
5.13. Pfizer Inc
5.14. Sanofi S.A.
5.15. Takeda Pharmaceutical Company Limited

6. Appendix
6.1. Discussion Guide
6.2. License & Pricing

List of Figures

FIGURE 1. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 2. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET: FPNV POSITIONING MATRIX
FIGURE 3. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET: SHARE, BY KEY PLAYER, 2020
FIGURE 4. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET, BY TYPE

List of Tables

TABLE 1. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET: MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016-2020
TABLE 3. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 4. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET: SCORES
TABLE 5. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET: BUSINESS STRATEGY
TABLE 6. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET: PRODUCT SATISFACTION
TABLE 7. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET: RANKING
TABLE 8. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET: SHARE, BY KEY PLAYER, 2020
TABLE 9. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET: MERGER & ACQUISITION
TABLE 10. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 11. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 12. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET: INVESTMENT & FUNDING
TABLE 13. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 14. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET: LICENSE & PRICING

Companies Mentioned

Astellas Pharma Inc
AstraZeneca PLC
Bristol Myers Squibb
C.H. Boehringer Sohn AG & Ko. KG
Celgene Corporation
Eisai Co., Ltd
Eli Lilly and Company
F. Hoffmann-La Roche Ltd
GlaxoSmithKline PLC
Merck KGaA
Novartis International AG
Orion Corporation
Pfizer Inc
Sanofi S.A.
Takeda Pharmaceutical Company Limited